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Abstract
Background:  The drug-eluting stents have decreased the incidence of instent restenosis
compared to bare metal stents. But, the incidence of late and very late stent thrombosis has
increased with the drug-eluting stents.
Case presentation: We are here, reporting three cases of incredibly late instent thrombosis,
each one occurring after more than 50 months of drug-eluting stent placement.
Conclusion: The occurrence of stent thrombosis as late as 5 years has been reported in literature.
This highlights the importance that there may be no limit to the time duration to the occurrence
of very late stent thrombosis and dual antiplatelet therapy with aspirin and clopidogrel may have to
be continued indefinitely in patients with drug-eluting stents.
Background
Though drug-eluting stents (DES) when compared with
bare metal stents (BMS) have decreased the incidence of
instent restenosis and subsequent target vessel revascular-
ization, studies have highlighted the increased incidence
of late and very late stent thromboses (VLST) with DES
and their potential adverse clinical outcomes.
As per the standard definition from the Academic
Research Consortium (ARC) stent thrombosis (ST) can be
called acute, subacute, late and very late based on the tim-
ing [1]. An acute ST is defined as ST during percutaneous
coronary intervention (PCI) or within the following 24
hours, subacute ST as between 1 and 30 days following
PCI, late ST as between 1 month and 1 year following the
PCI, and very late ST as more than one year following the
PCI. The ARC has also standardized the definitions of a
definite ST, possible ST and probable ST based on differ-
ent criteria.
The longest reported interval between the implantation
and thrombosis of a DES is about 67 months [2]. Here we
report three cases of incredibly late ST occurring after 51
months (case 1), 58 months (case 2) and more than 50
months (case 3) from implantation, respectively. To our
knowledge, the duration of 58 months in one of our cases
represents one of the longest reported latencies from the
placement to the occurrence of thrombosis described in
the literature for the DES.
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Case presentation
Case report 1
A 60 year old Caucasian male presented with an acute cor-
onary syndrome in October 2003. He had a history of
hypertension, tobacco use, dyslipidemia and a family his-
tory of coronary artery disease. The coronary angiogram
(CAG) showed 80% focal stenosis in the distal portion of
the right coronary artery (RCA). The lesion was treated
with a 2.5 × 18 mm sirolimus eluting coronary stent
(Cypher stent, Johnson & Johnson, New Brunswick, New
Jersey, USA) deployed at 12 atmospheres and post dilated
at 14 atmospheres with a 2.75 mm non-compliant bal-
loon. There was TIMI (Thrombolysis in myocardial infarc-
tion) grade 3 flow with no complications. He was
discharged on aspirin and clopidogrel along with other
standard medical regimen. While continuing to take the
dual anti-platelet therapy he was readmitted on Novem-
ber 2004 with unstable angina. The CAG at this time
showed a patent distal RCA stent but the posterior
descending artery (PDA) was critically narrowed. The PDA
lesion was treated with a 2.5 × 13 mm sirolimus eluting
stent (Cypher stent, Johnson & Johnson, New Brunswick,
New Jersey, USA) deployed at 11 atmospheres with satis-
factory results and no complications. He was once again
discharged on dual anti-platelet therapy.
In January 2008, the patient was readmitted with an acute
inferior wall ST-elevation myocardial infarction (STEMI).
He had continued on aspirin and clopidogrel since his
second stent was placed. His aspirin and clopidogrel were
held 10 days prior to this episode for a dental procedure.
On admission an emergent cardiac catheterization was
performed which showed a thrombotic total occlusion of
the previously placed DES in the distal RCA (Figure 1).
The lesion was successfully dealt with using standard per-
cutaneous intervention procedures (Figure 2). The post-
interventional course was uneventful and the patient was
discharged on dual anti-platelet therapy (DAT) WITH
aspirin 325 mg and clopidogrel 75 mg, to be continued
indefinitely.
Case report 2
A 66 year old Caucasian male with the past history of
hypertension and dyslipidemia underwent a cardiac cath-
eterization in December 2003 because of exertional
angina and a positive stress test. It showed critical disease
with 90% stenoses of both the mid left anterior descend-
ing artery (LAD) and the mid RCA. The sirolimus eluting
coronary stents (Cypher stent, Johnson & Johnson, New
Brunswick, New Jersey, USA) 2.75 × 18 mm and 2.5 × 18
mm were deployed at 17 atmospheres in both the mid
LAD and RCA lesions, respectively. Using a Quantum
Maverick 3.0 × 12 mm balloon, both were post-dilated at
18 atmospheres with a 0% residual stenosis, TIMI grade 3
flow and no peri-procedural complications. He was sub-
sequently discharged on aspirin, clopidogrel and other
standard medical regimen. The clopidogrel was stopped
after the recommended treatment period of 3 months and
after which he was continued on aspirin alone.
Angiogram showing Thrombotic occlusion of DES in distal  Right Coronary Artery Figure 1
Angiogram showing Thrombotic occlusion of DES in 
distal Right Coronary Artery.
Angiogram of the distal Right Coronary Artery lesion after  standard PCI Figure 2
Angiogram of the distal Right Coronary Artery lesion 
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In October 2008, nearly 5 years post-stent placement, the
patient was readmitted with an acute antero-septal ST-ele-
vation MI. His aspirin was held about a week prior to this
episode for a colonoscopy. An emergent left heart cathe-
terization was performed which revealed a 100% occlu-
sion of the mid LAD stent secondary to thrombosis and a
70% to 80% stenosis of the RCA within the stent second-
ary to likely thrombus (Figure 3). The patient was loaded
with 600 mg clopidogrel and abciximab infusion was
started prior to the procedure. Both the lesions were dealt
with successfully using standard procedural techniques
with 0% residual stenosis and TIMI III flow (Figure 4). The
2D echocardiogram showed an akinetic left ventricular
antero-apical region consistent with a LAD territory infarct
and an ejection fraction of 35% to 40%. The post-inter-
ventional course was uneventful and the patient was dis-
charged on aspirin 325 mg and clopidogrel 75 mg, to be
taken indefinitely.
Case report 3
A 69 year old Caucasian male with a past history of hyper-
tension, type 2 diabetes, dyslipidemia, coronary artery
disease, history of coronary artery bypass graft to LAD,
RCA and diagonal arteries in 1998, underwent an elective
PCI with a paclitaxel-eluting coronary stent (Taxus Stent,
Boston Scientific, Massachusetts, USA) to the proximal
left circumflex artery in the early 2004 at another hospital.
Our access to those records was limited. The patient was
continued on DAT with aspirin and clopidogrel for nearly
6 months post-stent implantation following which clopi-
dogrel was discontinued on account of extensive bruising.
More than 4 years later, in December 2008, the patient
was admitted to our hospital with acute retrosternal chest
pain associated with nausea and vomiting. The EKG
showed sinus rhythm with an old left bundle branch
block. The biomarkers were positive with a troponins I of
39.9 and a creatinine phosphokinase (CPK) of 1259. He
underwent an emergent cardiac catheterization that
revealed patent bypass grafts but also showed a thrombus
in the previously placed stent in the proximal left circum-
flex with a 99% angiographic stenosis and TIMI 1 to 2
flow (Figure 5). The lesion was successfully treated with a
percutaneous transluminal coronary angioplasty includ-
ing mechanical thrombectomy using an X-Port catheter
and using a Quantum Maverick 3.5 × 18 mm balloon with
restoration of TIMI 3 flow and no significant residual ste-
nosis or evidence of distal embolization (Figure 6). The
post-interventional course was uneventful and the patient
was discharged on DAT.
Conclusion
The very late stent thrombosis (VLST) which occurs more
than one year after stent implantation is a serious compli-
cation of first generation DES. The VLST has been reported
to occur at rates varying between 0.2 to 0.7% of the DES-
treated patients in various studies [3-7]. However, the
incidence of VLST may be higher in real life than in clini-
Angiogram showing complete thrombosis of DES in mid Left  Anterior Descending artery Figure 3
Angiogram showing complete thrombosis of DES in 
mid Left Anterior Descending artery.
Angiogram of mid Left Anterior Descending Artery lesion  after Standard PCI Figure 4
Angiogram of mid Left Anterior Descending Artery 
lesion after Standard PCI.Cases Journal 2009, 2:9303 http://www.casesjournal.com/content/2/1/9303
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cal trials because the real-life patients are potentially
sicker, their lesions may be more complex, and follow up
is longer.
The etiology of ST with DES is not yet completely eluci-
dated. The discontinuation of thienopyridine therapy was
shown to be a major determinant of ST within the first 6
months but discontinuation after 6 months did not pre-
dict the occurrence of ST in one study (hazard ratio 0.94)
[8]. Several other determinants including renal failure,
diabetes, low ejection fraction, in-stent restenosis, bifurca-
tion lesions, type C lesions, and a trend for smaller-diam-
eter stents have also been suggested to be the significant
correlates of late stent thrombosis [6,9]. Besides these risk
factors, delayed arterial healing post-stent implantation in
combination with other risk factors like local hypersensi-
tivity reaction, ostial location, mal-apposition or incom-
plete apposition of the stent and strut penetration into a
necrotic lipid core have all been suggested to play a role in
late stent thrombosis [10]. The cases of single DES throm-
bosis in patients with multiple intracoronary DES of the
same duration suggest that the factors like incomplete
stent apposition and/or, under-expansion and/or, signifi-
cant residual reference-segment disease play a considera-
ble role in the pathogenesis.
Pathologically, incomplete neointimal coverage leading
to a delayed arterial healing in DES is probably an impor-
tant explanation for the increased risk of thrombosis
(especially late or very late ST) in DES compared to BMS.
A serial angioscopic follow up study comparing BMS and
DES group of patients demonstrated that neointimal cov-
erage was complete in all patients with BMS at ten months
while the majority of patients with DES (sirolimus stents)
had incomplete coverage at 21 months (P < 0.05) [11]. It
has also shown that the mural red thrombi were seen only
in patients with DES and in those with incomplete
neointimal coverage. From a registry study of 40 autopsies
of DES (68 stents) by Joner et al, 23 DES cases of more
than 30 days duration were compared with 25 matched
autopsies of BMS implantation [10]. Out of those 23
patients with DES more than 30 days old, 14 had evidence
of late stent thromboses and the delayed arterial healing
was more pronounced in DES patients with late stent
thrombosis than in those without stent thrombosis. In the
same study, DES also showed poorer endothelialization
(55.8 +/- 26.5%) compared with BMS (89.8 +/- 20.9, p =
0.0001).
Ever since the approval of DES in 2003, cases of very late
ST with increasing time interval between the implantation
of DES and the thrombotic events are being reported. To
our knowledge, the duration of 58 months in one of our
cases represents one of the longest latency from implanta-
tion to thrombosis described in the literature for the DES.
More and more reporting of such cases is extremely
important to unravel the extent of the risk. These cases
highlight the fact that there may be no limit to the time
period for the definition of VLST, especially upon cessa-
Angiogram showing thrombosis of DES in Left Circumflex  artery Figure 5
Angiogram showing thrombosis of DES in Left Cir-
cumflex artery.
Angiogram of Left Circumflex after standard PCI Figure 6
Angiogram of Left Circumflex after standard PCI.Cases Journal 2009, 2:9303 http://www.casesjournal.com/content/2/1/9303
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tion of antiplatelet therapy. The optimal duration of
antiplatelet therapy (whether single or dual) remains
questionable although the 2007 ACC/AHA/SCAI focused
update of the 2005 PCI guidelines recommended clopi-
dogrel 75 mg daily for at least 12 months in patients who
receive a DES [12].
The guidelines might have to be revised recommending
continuation of antiplatelet therapy for an unlimited
period of time (even lifelong) for patients with a DES. The
newer antiplatelet therapy like prasugrel (TRITON TIMI
38) also may affect treatment algorithm [13]. More
importantly, before implanting a DES in any patient
(either on-label or off-label use), strong considerations
should be given to the degree of risk for restenosis and the
patient's ability to comply with long-term dual antiplate-
let therapy. DES implantation should be avoided if there
is any doubt that the patient can comply with prolonged
dual antiplatelet therapy and if the likelihood of future
bleeding risk or necessity for surgical/invasive procedures
is high.
Even if recommended to continue the antiplatelet therapy
indefinitely in DES patients, the issue of incomplete
neointimal coverage after a long term period with DES
remains unresolved and little is known whether continu-
ing the antiplatelet therapy itself will counterbalance the
risks of having exposed stent struts, as cases of very late ST
have also occurred while the DES patients were taking
uninterrupted dual antiplatelet therapy [14]. However, 34
out of 36 cases of late ST in DES in one analysis were with-
out clopidogrel at the time of the event [15]. It makes a
stronger argument for continued long term DAT in such
patients. Larger randomized studies with longer follow-
ups are needed to answer these questions with certainty.
The new generation DES may behave differently and
likely to have an improved safety profile. But, the data is
very limited at this time and there is a need for large regis-
tries, clinical trials and head to head comparisons in a
variety of situations before we conclusively prove they
have greater efficacy and improved safety.
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